US 12,227,570 B2
Anti-CEACAM6 antibodies and methods of use
Hau Wan Leung, Singapore (SG); Andre Boon Hwa Choo, Singapore (SG); Mei Yee Vanessa Ding, Singapore (SG); Shao Weng Daniel Tan, Singapore (SG); and Narayanan Gopalakrishna Iyer, Singapore (SG)
Assigned to Singapore Health Services PTE LTD, Singapore (SG); and Agency for Science, Technology and Research, Singapore (SG)
Filed by Singapore Health Services PTE LTD, Singapore (SG); and AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Singapore (SG)
Filed on Oct. 23, 2023, as Appl. No. 18/383,043.
Application 18/383,043 is a continuation of application No. 17/560,232, filed on Dec. 22, 2021, granted, now 11,820,821.
Application 17/560,232 is a continuation of application No. 16/341,052, granted, now 11,236,160, previously published as PCT/SG2017/050509, filed on Oct. 10, 2017.
Claims priority of application No. 10201608481W (SG), filed on Oct. 10, 2016.
Prior Publication US 2024/0254221 A1, Aug. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 47/6415 (2017.08); A61K 47/68031 (2023.08); A61K 47/6857 (2017.08); A61K 51/1048 (2013.01); A61P 35/00 (2018.01); C07K 16/30 (2013.01); C07K 16/44 (2013.01); G01N 33/57473 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); C07K 2317/732 (2013.01)] 12 Claims
 
1. An antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GNTFTSYVMH (SEQ ID NO: 3); a VHCDR2 having the amino acid sequence YINPYNDGTKYNEKFKG (SEQ ID NO: 4); and a VHCDR3 having the amino acid sequence STARATPYFYAMDY (SEQ ID NO: 5); and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLWSVNQNSYLS (SEQ ID NO: 6), a VLCDR2 having the amino acid sequence GASIRES (SEQ ID NO: 7), and a VLCDR3 having the amino acid sequence QHNHGSFLPYT (SEQ ID NO: 8), wherein the antigen-binding protein, or an antigen-binding fragment thereof, comprises a monomethyl auristatin E (MMAE) conjugated thereto.